ECTRIMS 2022 Conference Coverage

October 26-28 2022

Multiple Sclerosis News Today is providing comprehensive and in-depth virtual coverage of the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

November 7, 2022

MS News Notes: Stem Cell Transplant Versus DMTs, Treatment Efficacy, Cancer Risk, Employment

Welcome to “MS News Notes,” where I comment on multiple sclerosis (MS) news stories that caught my eye last week. The articles in today’s column came from the annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held Oct. 26–28 in Amsterdam. Most of them deal with disease-modifying therapies (DMTs). […]

November 7, 2022

#ECTRIMS2022 – ATA188 Could Be ‘Game Changing’ for Progressive MS

In an early clinical trial, Atara Biotherapeutics’ investigational treatment ATA188 stabilized or eased disability in most people with nonactive, progressive forms of multiple sclerosis (MS) — with those benefits now having been sustained for up to four years. For MS patients, in whom disability progressively accumulates over time, and for whom few disease-modifying therapies (DMTs) […]

November 4, 2022

#ECTRIMS2022 – 3-year Data Show Evobrutinib Safely Lowers Relapses

Long-term use of the investigational BTK inhibitor evobrutinib among people with relapsing forms of multiple sclerosis (MS) continues to maintain MS relapse rates, and keep MRI lesion activity low. That’s according to up to 3.5 years of data from a Phase 2 trial (NCT02975349) and its open-label extension (OLE) phase, which are evaluating the therapy […]

November 4, 2022

#ECTRIMS2022 – Vumerity Lowers RRMS Activity Over 2 Years

Up to two years of Vumerity (diroximel fumarate) treatment was generally well-tolerated and led to significant decreases in disease activity in people with relapsing-remitting multiple sclerosis (RRMS), according to a final analysis of data from the open-label EVOLVE-MS-1 Phase 3 clinical trial. Indirect comparisons of Vumerity-treated patients against those who received Ponvory (ponesimod) or Aubagio (teriflunomide) […]

November 3, 2022

#ECTRIMS2022 – New Analyses Say Ublituximab Is Superior to Aubagio

The experimental therapy ublituximab works better than the approved treatment Aubagio (teriflunomide) at easing disability independently of relapses, and at reducing overall disease activity, in adults with relapsing forms of multiple sclerosis (MS). That’s according to exploratory analyses of pooled data from the identical ULTIMATE I (NCT03277261) and ULTIMATE II (NCT03277248) Phase 3 clinical trials, […]

November 3, 2022

#ECTRIMS2022 – Ocrevus Seems to Beat Rituximab in Reducing Relapses

Ocrevus (ocrelizumab), an anti-CD20 therapy developed by Genentech, seems to be superior to rituximab at lowering relapse rates among patients with relapsing-remitting multiple sclerosis (RRMS), according to data from two large MS registries. Overall, the findings suggest that rituximab cannot be considered just as good as — or non-inferior to — Ocrevus, despite their similar […]

November 3, 2022

#ECTRIMS2022 – Job Prospects Can Slowly Take a Hit After CIS Diagnosis

In the years after a diagnosis of clinically isolated syndrome (CIS) — a first episode of neurological symptoms suggestive of multiple sclerosis (MS) — the odds of maintaining employment progressively decrease, according to a recent study. The risk of decreasing or losing employment was particularly high among individuals who later transitioned to a clinical diagnosis […]

November 2, 2022

#ECTRIMS2022 – DMTs Ease SPMS Disability Early but Not Over Time

Early use of disease-modifying therapies (DMTs) among people with secondary progressive multiple sclerosis (SPMS) may lead to overall lower levels of disability, according to a new analysis. But staying on treatment does not appear to significantly slow disability progression over time. People with SPMS who used DMTs early on consistently had lower scores on the […]

November 2, 2022

#ECTRIMS2022 – Analyses Weigh Stem Cell Transplant Versus DMTs

Autologous hematopoietic stem cell transplant (aHSCT) is superior to Gilenya (fingolimod) and Tysabri (natalizumab) at preventing relapses and reducing disability in people with highly active relapsing-remitting multiple sclerosis (RRMS). In turn, aHSCT appears to be as effective as Ocrevus (ocrelizumab) in RRMS patients and also was not superior to Tysabri in people with progressive MS. […]

November 2, 2022

#ECTRIMS2022 – 2 Brain Lesion Types Linked to Greater Disability

Recently diagnosed multiple sclerosis (MS) patients with two forms of chronic active brain lesions — slowly expanding lesions (SELs) and paramagnetic rim lesions (PRLs) — on their MRI scans experience greater disability progression than those with SELs only, a small study suggests. Also, the slowly expanding lesions are more common among patients than the other […]

November 1, 2022

#ECTRIMS2022 – Tecfidera Lowers Risk of 1st Symptoms in RIS in Trial

Treatment with Tecfidera (dimethyl fumarate) significantly reduces the risk of experiencing the first multiple sclerosis (MS) symptoms in adults with radiologically isolated syndrome (RIS), according to data from a Phase 4 clinical trial. RIS is a condition in which patients have MS-like lesions on MRI scans, but lack typical symptoms of the disease. This is […]

November 1, 2022

#ECTRIMS2022 – High-efficacy DMTs Linked to Cervical Cancer Risk

Exposure to high-efficacy disease-modifying therapies (DMTs) is associated with an increased risk of cervical abnormalities in women with multiple sclerosis (MS), recent data suggest. The findings are consistent with previous reports showing these treatments may raise the risk of certain cancers, likely as a consequence of their immune-modulating effects. While larger studies are needed to […]

October 31, 2022

MS News Notes: ECTRIMS, Ocrevus, Kesimpta, Epstein-Barr, DMTs

Here are a few multiple sclerosis (MS) stories that caught my eye last week. Two of them came out of this year’s Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Ocrevus treatment More than 250,000 people with MS have been treated with the disease-modifying therapy (DMT) Ocrevus (ocrelizumab) since its […]

October 31, 2022

#ECTRIMS2022 – Genetic Variants Tied to Worse MS ID’d in New Study

Genetic variants in genes mostly active in the brain and spinal cord — the central nervous system — are associated with the severity of multiple sclerosis (MS), and linked to a faster accrual of disability and greater signs of brain tissue damage, a new study found. Importantly, researchers estimated that nearly 13% of the variability […]

October 31, 2022

#ECTRIMS2022 – Relapse-free Progression Evident in Pediatric MS

Disability progression in the absence of relapses is less common in children and adolescents with multiple sclerosis (MS) than among people with adult-onset disease, according to data covering more than 5,000 patients with relapsing forms of MS. Nevertheless, this form of progression — called progression independent of relapse activity, or PIRA — still accounted for […]

October 31, 2022

#ECTRIMS2022 – ATA188 Still Easing Disability in Progressive MS Patients

The investigational immunotherapy ATA188 continues to ease disability and prevent brain tissue shrinkage in people with progressive forms of multiple sclerosis, according to the data, now reaching up to four years, on patients in an ongoing clinical trial. People who achieved confirmed disability improvement also showed potential signs of remyelination, or the restoration of the protective myelin sheath […]

October 28, 2022

#ECTRIMS2022 – Smartphone Tap Speed May Help in Monitoring MS

Tap speed — or how quickly one types on a smartphone keyboard — may be a useful tool for monitoring multiple sclerosis (MS) severity and detecting the transition to a progressive form of the disease, according to new research data. Results demonstrated that slower tapping speeds were linked to worse clinical measures of disease in […]

October 28, 2022

#ECTRIMS2022 – Long-term Gilenya Reduces Pediatric Relapses

Long-term treatment with Gilenya (fingolimod) continues to be safe and lower the rate of relapses in children and adolescents with multiple sclerosis (MS) more than Avonex (interferon beta-1a) does. That’s according to up to six years of data from the ongoing PARADIGMS Phase 3 trial (NCT01892722), wherein participants were given one of the therapies for two […]

October 28, 2022

#ECTRIMS2022 – EBV Antibodies Precede Early Nerve Damage Signs

An infection with the Epstein-Barr virus (EBV) consistently preceded elevations in neurofilament light chain (NfL), an early biomarker of nerve cell damage, in people who went on to develop multiple sclerosis (MS), new data show. An increase in NfL levels, which is thought to occur before the clinical emergence of MS, was observed about 5–10 […]

October 27, 2022

#ECTRIMS2022 – Poor Myelin Repair Offers Clues in Disease Progression

Remyelination, or regeneration of the myelin sheath that’s progressively damaged and lost in multiple sclerosis (MS), may be less effective for those who develop MS later in life, new research suggests. People with late-onset MS (LOMS) whose disease appears after age 50 have significantly fewer oligodendrocytes – the cells chiefly responsible for making myelin in […]

October 27, 2022

#ECTRIMS2022 – Study Examines Ocrevus Use Before, During Pregnancy

Treatment with Ocrevus (ocrelizumab) before or during pregnancy does not seem to increase the risk of major pregnancy or infant complications, with 79% of the pregnancies leading to live births, according to data from more than 2,000 women with multiple sclerosis (MS). The results were shared at the 38th Congress of the European Committee for Treatment […]

October 26, 2022

#ECTRIMS2022 – Fertility Treatment Won’t Raise Relapse Risk for Women

Fertility treatments do not significantly increase the risk of relapse in women with multiple sclerosis (MS), even among those who undergo treatment protocols associated with greater levels of hormone exposure, according to a recent U.S.-based analysis. Older age, a longer MS duration, and the use of MS disease-modifying treatments (DMTs) were all factors associated with […]

October 26, 2022

#ECTRIMS2022 – 2-year Ocrevus Effective for Early MS Patients: Data

Nearly 80% of people with early-stage relapsing-remitting multiple sclerosis (RRMS) show no evidence of disease activity after two years of treatment with Ocrevus (ocrelizumab), according to updated data from the ENSEMBLE Phase 3b trial. More than 88% of the patients were negative for MRI activity, meaning they had no new or enlarging lesions or lesions […]

October 24, 2022

MS News Today to Cover ECTRIMS 2022 Beginning Oct. 26

Multiple Sclerosis News Today is providing comprehensive coverage of the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), taking place Oct. 26-28 in Amsterdam, as well as virtually. Each year, MS News Today brings the multiple sclerosis (MS) community highlights of the ECTRIMS conference, aiming to bridge the gap […]

Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.